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bjectives The purpose of this study was to use intravascular ultrasound (IVUS) to investigate
hronic arterial responses at the site of and adjacent to overlapping paclitaxel-eluting TAXUS stents
PES) compared with overlapping bare-metal stents (BMS).
ackground Increased paclitaxel dose in the PES-overlap region might be associated with arterial
oxicity expressed as excessive expansive remodeling, incomplete stent apposition, or aneurysm for-
ation.
ethods In the TAXUS-V and -VI trials, 51 patients with overlapping stents (27 PES and 24 BMS)
ere imaged with serial IVUS immediately after procedure and at 9 months. The IVUS measure-
ents included intimal hyperplasia (IH), peri-stent plaque plus media (P&M), and external elastic
embrane (EEM) areas. Vascular responses were assessed at the proximal and distal single stent
trut regions and the central overlap region.
esults Compared with BMS, all 3 PES stent regions showed: 1) signiﬁcantly decreased IH (proxi-
al: 0.97  1.06 mm2 vs. 3.12  2.40 mm2, overlap: 0.74  0.91 mm2 vs. 3.23  1.75 mm2, distal:
.88  0.85 mm2 vs. 2.69  1.49 mm2, all p  0.05); and 2) increased P&M and EEM areas (Delta
&M; proximal: 0.96  1.36 mm2 vs. 0.02  1.48 mm2, overlap: 1.56  1.88 mm2 vs. 0.29  1.82
m2, distal: 1.03  1.81 mm2 vs. 0.11  0.89 mm2, all p  0.05). The IH and changes in EEM and
&M areas were not signiﬁcantly different in both the BMS and PES groups comparing the single
tent strut and overlap regions. Incomplete stent apposition did not occur at the site of overlapping
ES in any patient.
onclusions Nine months after stent implantation, neointimal tissue growth was reduced and ex-
ansive remodeling was greater with PES compared with BMS—effects that were not exaggerated
t the overlap region of PES. (J Am Coll Cardiol Intv 2008;1:161–7) © 2008 by the American
ollege of Cardiology Foundation
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162rowing evidence supports the clinical benefit of paclitaxel-
luting stents (PES) across a broad range of patient and
esion types (1–4). However, stent overlap is associated with
ore frequent angiographic restenosis even with drug-
luting stents (DES) (2). Whereas only 1 stent/lesion was
mplanted in the TAXUS-II and -IV trials, TAXUS-V and
VI permitted overlapping stents for longer lesions
1,2,5,6). An experimental study using balloon-injured rab-
it iliac arteries showed that overlapping PES resulted in
elayed healing compared with adjacent proximal and distal
ingle PES-layer segments (7) and greater inflammation
nd fibrin deposition than overlapping sirolimus-eluting
tents (SES). Conversely, studies in porcine coronary artery
odels have shown comparable healing for overlapping
ES (8). Finally, clinical outcomes after overlapping PES
ompared with overlapping SES were similar in some
real-world observational studies
(9,10).
Vascular responses after stent
implantation may be assessed
with serial angiographic and in-
travascular ultrasound (IVUS)
measurements. Although per-
cent in-stent obstruction in the
overlap region based solely on
follow-up IVUS analysis was
performed in the TAXUS trials
(11), peri-stent responses to
DES (i.e., outside the stent or
between the stent and the vessel
wall) have been incompletely
characterized (12). Early assess-
ments of volumetric changes
outside DES reported a dose-
dependent and partially revers-
ible increase in arterial dimen-
sions over time when compared
with bare-metal stents (BMS)
13). These findings were hypothesized to reflect a con-
rolled biologic response to the implantation of polymeric
ES.
Along with the comparison of different dose formula-
ions, such as slow- versus moderate-release PES in the
AXUS-II trial (14), the implantation of overlapping
tents represents another internally controlled model
llowing examination of chronic vessel reactions to vary-
ng local paclitaxel doses by comparing the proximal and
istal single stent strut regions with the central overlap
egion. The objective of the present analysis was to use
erial (baseline and follow-up) IVUS studies from the
andomized TAXUS-V and -VI multicenter studies to
tudy chronic arterial responses to overlapping PES
bbreviations
nd Acronyms
MS  bare-metal stent(s)
SA  cross-sectional area
ES  drug-eluting stent(s)
EM  external elastic
embrane
H  intimal hyperplasia
area)
SA  incomplete stent
pposition
VUS  intravascular
ltrasound system
ES  paclitaxel-eluting
tent(s)
&M  plaque and media
area)
ES  sirolimus-eluting
tent(s)mplantation. pethods
atient selection. The study designs and clinical and angio-
raphic outcomes of the prospective, multicenter, double-
lind, controlled TAXUS-V and -VI trials have been
escribed elsewhere (2,6). Briefly, TAXUS-V randomized
,156 patients to either slow-release PES or visually indis-
inguishable Express2 BMS (both Boston Scientific Corp.,
atick, Massachusetts). The TAXUS-VI randomized 446
atients to either moderate-release PES or Express2 BMS
both Boston Scientific Corp.). Patients with single de novo
esions, 10 to 46 mm in length, in a native coronary artery
ith reference vessel diameter between 2.25 and 4.0 mm
ere enrolled in TAXUS-V, whereas patients with single de
ovo lesions 18 to 40 mm long in a native coronary artery
ith reference vessel diameter between 2.5 and 3.75 mm
ere enrolled in TAXUS-VI. By protocol, multiple stents
ere required for lesions 26 mm in length, in which case
mm of stent overlap was specified in both studies to ensure
he absence of gaps. Of 1,602 total patients, 80 who were
reated with overlapping stents were assigned to a substudy
hat included baseline and follow-up IVUS imaging and
nalysis. However, among these 80 patients, 19 did not have
VUS at implantation; and the overlap region could not be
ifferentiated from the adjacent single-PES layer in an
dditional 10 patients. The remaining 51 patients (27 PES
nd 24 BMS) were included in the present study. All
atients provided written informed consent, and this inves-
igation was approved at the local institutional review board
r ethics committee of each participating center.
uantitative IVUS analysis. The IVUS imaging was per-
ormed after intracoronary administration of 0.1 to 0.2 mg
itroglycerin with motorized pullback (0.5 mm/s) and
ontemporary commercial scanners. Images were recorded
nto s-VHS videotape or digitally onto CD or MO disc for
ffline core laboratory analysis. These images were analyzed
ccording to published standards, with computerized
lanimetry (Tapemeasure, Indec Inc., Mountain View,
alifornia) by an independent core laboratory (Washington
ospital Center, Washington, DC) that remained blinded
o treatment allocation (15).
The stented lesion was divided into 3 regions according
o location: 1) proximal single stent layer; 2) middle over-
apping double stent layers; and 3) distal single stent layer
Fig. 1). External elastic membrane (EEM), stent, and
umen cross-sectional areas (CSA) were measured for each
illimeter. Peri-stent plaque and media (P&M) CSA
P&M EEM stent) and intimal hyperplasia (IH) CSA
IH  stent  lumen) were calculated for each millimeter.
he results are expressed as the average of the individual
ross-sectional slices within each region. Although every
ttempt was made to analyze EEM CSA for each millime-
er throughout the stented segment, it was not possible in all
atients, because in come cases the stent artifact obscured
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163he media-adventitia border. Therefore, for the purpose of
he current analysis, we excluded segments in which 25%
f the length of the EEM was not identifiable (16). As a
esult, EEM analysis was possible in 26 patients (96.3%) in
he PES group and in 21 patients (87.5%) in the BMS
roup.
Incomplete stent apposition (ISA) was defined as 1 or
ore stent struts clearly separated from the vessel wall with
vidence of blood flow behind the struts and not overlap-
ing a side branch (13,17). Incomplete stent apposition was
lassified as 1 of 3 types. Resolved ISA was defined as ISA
hat was present at implantation but disappeared during
ollow-up. Persistent ISA was defined as ISA that was
resent both at implantation and at follow-up. Late ac-
uired ISA was defined as ISA that was absent at implan-
ation but present at follow-up. When ISA was detected,
Figure 1. Three Regions in the Overlapping Stented Lesion
The stented lesion was divided into 3 regions (proximal single stent layer, mid
Table 1. Baseline Characteristics
Age, yrs 6
Gender male, %
Current smoking, %
Diabetes mellitus, %
Hypertension, %
Unstable angina, %
Prior myocardial infarction, %
Statin prescription at discharge, %*
Treated vessel
Left anterior descending coronary artery, %
Left circumﬂex coronary artery, %
Right coronary artery, %
Reference vessel diameter, mm
Lesion length, mm 2
Total stent length, mm 3
Average stent diameter, mm
*TAXUS-V patients only.BMS bare-metal stent; PES paclitaxel-eluting stent.&M area was calculated as EEM CSA  stent CSA 
SA CSA.
tatistical analysis. Discrete variables are displayed as per-
entages and tested with Fisher exact test. Continuous
ariables are expressed as mean  SD and compared with
aired or unpaired Student t test or analysis of variance as
ppropriate. Linear regression was performed to assess the
orrelation between different IVUS outcomes. A value of p
0.05 was considered statistically significant.
esults
he PES and BMS groups were well-matched with respect
o clinical and lesion characteristics (Table 1). Average
mplanted stent length, stent diameter, and overlap length
erlapping double stent layers, and distal single stent layer).
 27) BMS (n  24) p Value
8.53 (27) 63.75 9.41 (24) 0.94
(19/27) 66.7% (16/24) 1.00
(3/27) 25.0% (6/24) 0.28
(11/27) 37.5% (9/24) 1.00
(18/27) 58.3% (14/24) 0.57
(12/27) 37.5% (9/24) 0.78
(6/27) 33.3% (8/24) 0.53
(17/20) 72.2% (13/18) 0.44
(12/27) 25.0% (6/24) 0.24
(6/27) 16.7% (4/24) 0.73
(9/27) 58.3% (14/24) 0.10
0.43 (27) 2.82 0.55 (24) 0.20
7.47 (27) 26.68 9.09 (24) 0.23
6.69 (27) 36.97 5.64 (24) 0.66
0.35 (27) 3.19 0.48 (24) 0.23PES (n
3.93
70.4%
11.1%
40.7%
66.7%
44.4%
22.2%
85.0%
44.4%
22.2%
33.3%
2.64
3.87
6.19
3.05
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164PES: 4.07  2.59 mm vs. BMS: 4.67  3.55 mm, p 
.50) were also comparable between the 2 groups (Table 2).
verlapping BMS. In lesions treated with BMS, there were
o statistically significant changes in serial (baseline vs.
ollow-up) measures of the EEM, stent, or peri-stent P&M
SA in the proximal, overlap, or distal stent regions.
umen CSA significantly decreased in both the single stent
nd overlap regions during the 9-month follow-up period
Table 2). The IH CSA and serial changes in EEM, stent,
Table 2. Intravascular Ultrasound Measurements at Post-Procedure and Fo
PES
Post-Procedure Follow-Up
Proximal region (single stent layer)
EEM area, mm2 15.17 4.30 (26) 16.11 4.72 (
Stent area, mm2 7.55 1.72 (27) 7.49 2.01 (
Lumen area, mm2 7.55 1.72 (27) 6.53 2.18 (
IH area, mm2 — 0.97 1.06 (
Peri-stent P&M area, mm2 7.61 3.03 (26) 8.57 3.09 (
Length, mm 15.89 5.80 (27) 15.96 4.92 (
Overlap region (double stent layers)
EEM area, mm2 14.23 3.91 (26) 15.67 4.41 (
Stent area, mm2 7.07 1.73 (27) 7.02 2.11 (
Lumen area, mm2 7.07 1.73 (27) 6.28 2.31 (
IH area, mm2 — 0.74 0.91 (
Peri-stent P&M area, mm2 7.10 2.57 (26) 8.66 2.73 (
Length, mm 4.07 2.59 (27) 4.04 2.79 (
Distal region (single stent layer)
EEM area, mm2 12.23 3.10 (26) 13.39 3.53 (
Stent area, mm2 6.73 1.58 (27) 6.81 1.94 (
Lumen area, mm2 6.73 1.58 (27) 5.93 2.06 (
IH area, mm2 — 0.88 0.85 (
Peri-stent P&M area, mm2 5.46 1.82 (26) 6.49 2.00 (
Length, mm 19.22 6.05 (27) 19.52 5.89 (
BMS bare-metal stent; EEM external elastic membrane; IH intimal hyperplasia; P&M plaqu
Table 3. Comparison of Vessel Responses Among the
Proximal Region
PES
IH area, mm2 0.97 1.06 (27)
∆Peri-stent P&M area, mm2 0.96 1.36 (26)
% ∆Peri-stent P&M area 15.6 21.3 (26)
∆EEM area, mm2 0.94 1.86 (26)
% ∆EEM area 6.8 12.8 (26)
BMS
IH area, mm2 3.12 2.40 (24)
∆Peri-stent P&M area, mm2 0.02 1.48 (21)
% ∆Peri-stent P&M area 3.0 19.0 (21)
∆EEM area, mm2 0.05 1.78 (21)
% ∆EEM area 0.7 11.1 (21)
Numbers in parenthesis indicate the number of segments available foANOVA analysis of variance; other abbreviations as in Table 2.nd peri-stent P&M area were not significantly different
mong the proximal, overlap, and distal BMS regions
Table 3). At follow-up, ISA was found in 4.2% of the
roximal regions but in none of the overlap or distal regions
p  0.36).
verlapping PES. Unlike BMS-treated lesions, there was an
verall increase in EEM and peri-stent P&M areas in all 3
ES segments (proximal, overlap, and distal). Stent CSA
id not change, but lumen CSA decreased during the
p
BMS
p Value Post-Procedure Follow-Up p Value
0.02 16.89 4.45 (21) 16.83 4.11 (21) 0.89
0.71 8.38 2.44 (24) 8.42 2.42 (24) 0.84
0.0006 8.45 2.51 (24) 5.43 2.38 (24) 0.0001
— — 3.12 2.40 (24) —
0.001 8.84 2.70 (21) 8.81 2.26 (21) 0.94
0.88 16.29 4.29 (24) 16.92 3.91 (24) 0.35
0.004 15.82 4.57 (21) 15.77 4.74 (21) 0.93
0.78 7.74 2.23 (24) 8.02 2.51 (24) 0.27
0.008 7.75 2.23 (24) 4.79 2.12 (24) 0.0001
— — 3.23 1.75 (24) —
0.0003 8.24 2.93 (21) 8.52 2.84 (21) 0.48
0.91 4.67 3.55 (24) 4.71 3.34 (24) 0.92
0.008 14.42 4.71 (24) 14.32 4.90 (24) 0.71
0.52 7.56 2.12 (24) 7.39 2.35 (24) 0.23
0.0004 7.57 2.13 (24) 4.72 2.19 (24) 0.0001
— — 2.69 1.49 (24) —
0.008 6.80 2.88 (24) 6.91 2.80 (24) 0.54
0.48 19.54 5.96 (24) 18.71 6.37 (24) 0.12
edia; PES paclitaxel-eluting stent.
gions
verlap Region Distal Region p ANOVA
.74 0.91 (27) 0.88 0.85 (27) 0.38
.56 1.88 (26) 1.03 1.81 (26) 0.21
9.3 38.4 (26) 30.1 66.5 (26) 0.28
.45 2.33 (26) 1.16 2.04 (26) 0.38
1.6 17.7 (26) 11.0 20.1 (26) 0.31
.23 1.75 (24) 2.69 1.49 (24) 0.85
.29 1.82 (21) 0.11 0.89 (24) 0.48
7.9 22.8 (21) 3.3 13.9 (24) 0.40
.05 2.64 (21) 0.10 1.30 (24) 1.00
1.0 16.8 (21) 0.8 8.5 (24) 0.95
ntravascular ultrasound analysis.llow-U
26)
27)
27)
27)
26)
27)
26)
27)
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165-month follow-up period (Table 2). More than three-
uarters of PES-treated lesions showed an increase in
eri-stent P&M area (proximal region: 73.1%; overlap
egion: 84.6%; and distal region: 80.8%). The increase in
EM CSA was similar to the increase in peri-stent P&M
SA, indicating that vessel remodeling outside the stent
aralleled the increase in peri-stent plaque (Table 3). Sim-
lar to BMS-treated lesions, IH area and serial changes in
eri-stent P&M and EEM CSA were not significantly
ifferent among the 3 regions (Table 3).
When the vascular responses to the slow-release PES
tents used in TAXUS-V were compared with the
oderate-release PES stents in TAXUS-VI, there was a
on-significant trend toward an increase in peri-stent
&M CSA in the moderate release PES-treated lesions
n all 3 regions: proximal region, 1.35  1.29 mm2 versus
.82  1.39 mm2 (p  0.39); central overlap region, 2.08
1.90 mm2 versus 1.37  1.89 mm2 (p  0.40); and
istal region 1.42  1.61 mm2 versus 0.88  1.90 mm2
p  0.51).
At 9 months follow-up among PES-treated lesions, ISA
as found in 11.1% of the proximal regions and in 7.4% of the
istal regions but not in any of the overlap regions (p 0.22).
MS versus PES stents. Comparing the vascular responses
etween PES and BMS, PES-treated lesions had reduced
H CSA in the proximal, overlap, and distal stent regions
Table 4). Although the difference did not reach statistical
ignificance, IH area tended to be less in the PES overlap
egion than in single strut PES regions (0.74  0.91 mm2
s. 0.93 0.92 mm2, p 0.27), whereas the opposite trend
as noted with BMS (3.23  1.75 mm2 vs. 2.90  1.72
m2, p  0.34). Furthermore, a greater increase in EEM
SA and peri-stent P&M CSA was present with PES
ompared with BMS, consistent with a greater degree of
xpansive remodeling (Table 4). There were no significant
ifferences in the frequency of ISA with PES and BMS in
ither the single stent or multiple overlapping stent regions.
For lesions treated with BMS, significant correlations
ere found between the degree of neointimal growth (IH)
nd the degree of outward remodeling (delta EEM) in all 3
egions (R  0.67, p  0.001 in the proximal; R  0.51, p
0.02 in the overlap; and R  0.50, p  0.01 in the distal
egion). However, these correlations were not observed in
esions treated with PES (R  0.12, p  0.54 in the
roximal; R  0.15, p  0.46 in the overlap; and R 
0.03, p  0.89 in the distal region).
iscussion
everal previous studies (angiographic [18,19], IVUS
20,21], angioscopic [22], and pathologic [7]) have ad-
ressed the issue of DES overlap. To our knowledge, there
ave been 2 published manuscripts in which IVUS analysis
as performed after overlapping DES implantations d20,21). Kang et al. (20) presented a comparison of IVUS
utcomes after different-DES overlap and same-DES over-
ap. The IH and EEM CSA at the overlapping site were not
ignificantly different between the 2 groups. However, there
as no comparison between DES overlap and BMS overlap.
n addition, this analysis was based only on follow-up IVUS
nalysis. Therefore, analyses of vessel remodeling and de-
ailed ISA (late acquired, persistent resolved) were not
ossible. Kawaguchi et al. (21) presented angiographic and
VUS outcomes after BMS overlap and 3 different types of
ES overlap implantation in patients with diabetes. Percent
H was less in the DES arms than the BMS arm in both
verlap and non-overlap regions. The EEM area at post-
rocedure and follow-up was analyzed. However, there was
o serial analysis. In addition, ISA was not observed at
ost-procedure and follow-up in all patients. Detailed serial
SA analysis was not possible. The present analysis repre-
ents the first manuscript to investigate vessel response
nside and outside the overlapping stent region, including
etailed ISA analysis. The major findings of this serial
VUS analysis of overlapping BMS and PES are as follows:
) compared with BMS-treated lesions, neointimal growth
n PES-treated lesions was significantly reduced in the
entral overlap region as well as the adjacent proximal and
Table 4. Comparison of Vessel Responses Between PES and BMS
PES BMS p Value
∆Peri-stent P&M area, mm2
Proximal region 0.96 1.36 (26) 0.02 1.48 (21) 0.02
Overlap region 1.56 1.88 (26) 0.29 1.82 (21) 0.02
Distal region 1.03 1.81 (26) 0.11 0.89 (24) 0.03
∆EEM area, mm2
Proximal region 0.94 1.86 (26) 0.05 1.78 (21) 0.07
Overlap region 1.45 2.33 (26) 0.05 2.64 (21) 0.04
Distal region 1.16 2.04 (26) 0.10 1.30 (24) 0.01
IH area, mm2
Proximal region 0.97 1.06 (27) 3.12 2.40 (24) 0.0001
Overlap region 0.74 0.91 (27) 3.23 1.75 (24) 0.0001
Distal region 0.88 0.85 (27) 2.69 1.49 (24) 0.0001
Late acquired ISA, n (%)
Proximal region 3.7% (1/27) 4.2% (1/24) 1.00
Overlap region 0.0% (0/27) 0.0% (0/24) —
Distal region 7.4% (2/27) 0.0% (0/24) 0.49
Persistent ISA, n (%)
Proximal region 7.4% (2/27) 0.0% (0/24) 0.49
Overlap region 0.0% (0/27) 0.0% (0/24) —
Distal region 0.0% (0/27) 0.0% (0/24) —
Resolved ISA, % n (%)
Proximal region 0.0% (0/27) 8.3% (2/24) 0.22
Overlap region 0.0% (0/27) 0.0% (0/24) —
Distal region 0.0% (0/27) 4.2% (1/24) 0.47
ISA incomplete stent apposition; other abbreviations as in Table 2.istal non-overlapped regions; 2) in all 3 regions the
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166ncrease in EEM and peri-stent P&M areas in PES-treated
esions was significantly greater than in BMS-treated le-
ions, and more than three quarters of PES-treated lesions
howed an increase in peri-stent P&M area in both single
trut and overlap regions; 3) among the 3 regions the
elative changes in IH, EEM, and peri-stent P&M areas
ere not significantly different in the both BMS and PES
roups; and 4) late acquired ISA was not observed in the
ES overlap region.
ascular remodeling after BMS and PES. An increase in
eri-stent P&M area after single PES implantation has
een observed in several studies with both slow- and
oderate-release PES in TAXUS-II and with slow-release
ES in TAXUS-IV (13,14,23). Similarly, Petronio et al.
16) reported a slight increase in peri-stent P&M area after
low-release PES implantation in the left anterior descend-
ng coronary artery. The present study thus confirms that
ES result in greater increases in EEM and peri-stent
&M areas than with BMS, at both the site of overlapping
tent struts and adjacent proximal and distal single stent
egions.
Whereas swine studies have shown comparable endothe-
ial cell coverage in the PES overlap zone (24), increased
aclitaxel or sirolimus elution from overlapping stents re-
ults in delayed healing and arterial toxicity in the rabbit
njured iliac model (7). Concern has thus been raised about
he potential for drug toxicity at the site of overlapping PES,
ecause of greater dose at this site (25). In TAXUS-II the
egree of peri-stent P&M area increase was exaggerated
ith moderate-release PES compared with the slow-release
ormulation, potentially explained by the greater paclitaxel
elease during either the burst phase within hours after stent
mplantation or the 3- to 8-fold total increased paclitaxel
ose eluted (in vitro). In the present study, however,
xaggerated vascular responses were not seen at the PES
verlap site, although a trend was present toward greater
xpansive remodeling with the moderate-release PES. High
oses of paclitaxel might also be expected to result in an
ncreased incidence of late acquired ISA. The anti-
etabolic effect of higher-dose paclitaxel theoretically
ight induce focal necrosis or apoptosis and generate a new
mpty space between the struts and the vessel wall (26). In
he present study, however, ISA also did not occur at the
ite of overlapping PES. Thus it would seem that overlap-
ing the commercially available slow-rate release PES does
ot result in excessive expansive remodeling or adverse
ascular responses, either because doubling the paclitaxel
ose remains below the toxic threshold or because the
rterial drug concentration in the overlap region might not
e twice as great as a single layer region (27). An additional
eason why vascular toxicity might not have been seen in the
resent report in contrast to the aforementioned animaltudy was that the length of overlap was significantly shorter
n the current study (mean 4 mm vs. 9.8 mm) (7).
H. In the current study, neointimal growth was signifi-
antly inhibited for PES compared with BMS in the overlap
egion and in the adjacent proximal and distal single strut
egions. Although the difference did not reach statistical
ignificance, the IH area was lowest in the overlap region of
ES-treated lesions compared with non-overlap regions.
lthough overlapping BMS struts might induce more
edial injury and a subsequent increase in IH (28,29), this
ffect seems to be counteracted by the increased drug density
t the overlap site of PES. Considering that immature
ndothelial coverage of stent strut is a predictor of late stent
hrombosis (30), a longer clinical follow-up of patients with
verlapping stents should be reassuring in future studies.
tudy limitations. Several limitations of the present study
hould be noted. Factors unrelated to the stent might play a
ole in vessel remodeling (31). Drugs such as statins and
ntihypertensive agents influence the change in plaque
olume (32–34). Although the prevalence of statin use was
imilar between PES and BMS groups, detailed lipid levels
ere not measured and this influence cannot be totally
xcluded. Not all patients in the substudy had baseline and
ollow-up IVUS. The entire length of the EEM could not
e measured in each patient, because of stent shadowing or
rtifact. Finally, this study comprised a relatively modest
umber of patients. It might be possible that a larger sample
ize would have been able to show significantly different
essel remodeling among the 3 regions in the lesions treated
ith overlapping PES. In addition, the number of patients
nrolled receiving the slow-release and moderate-release
ES was insufficient to allow definitive conclusions to be
rawn regarding differential vascular responses between the
PES types. Further IVUS investigation involving large
umbers of patients after DES overlap implantation is
arranted.
onclusions
ine months after implantation of overlapping stents,
eointimal tissue growth inside PES was significantly re-
uced compared with BMS at the expense of greater
xpansive remodeling. In the PES group, exaggerated vas-
ular responses were not present in the overlap region
ompared with the adjacent proximal or distal single stent
egions, and ISA was not observed at the site of PES
verlap.
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